search
Back to results

Metabolic Profile and Anthropometric Changes in Schizophrenia (MetS)

Primary Purpose

Metabolic Syndrome, Diabetes, Obesity

Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Olanzapine
Risperidone
Haloperidol
Sponsored by
Central Institute of Psychiatry, Ranchi, India
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Metabolic Syndrome focused on measuring Metabolic syndrome, Obesity, Diabetes

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age between 18-40 years
  • Diagnosis of schizophrenia
  • Drug naive on admission

Exclusion Criteria:

  • Other psychiatric co-morbidity
  • History of severe physical illness
  • Alcohol and substance abuse or dependence
  • History of pre-existing diabetes or hypertension
  • Family history of hypertension or diabetes

Sites / Locations

  • Central Institute of Psychiatry

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

1

2

3

Arm Description

Olanzapine

Risperidone

haloperidol

Outcomes

Primary Outcome Measures

Study of metabolic profile

Secondary Outcome Measures

Study of obesity and diabetes

Full Information

First Posted
September 21, 2007
Last Updated
September 21, 2007
Sponsor
Central Institute of Psychiatry, Ranchi, India
search

1. Study Identification

Unique Protocol Identification Number
NCT00534183
Brief Title
Metabolic Profile and Anthropometric Changes in Schizophrenia
Acronym
MetS
Official Title
Metabolic Profile and Anthropometric Changes in Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2007
Overall Recruitment Status
Completed
Study Start Date
June 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Central Institute of Psychiatry, Ranchi, India

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "
Detailed Description
we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Diabetes, Obesity
Keywords
Metabolic syndrome, Obesity, Diabetes

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
2006 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Olanzapine
Arm Title
2
Arm Type
Active Comparator
Arm Description
Risperidone
Arm Title
3
Arm Type
Active Comparator
Arm Description
haloperidol
Intervention Type
Drug
Intervention Name(s)
Olanzapine
Intervention Description
Olanzapine in dose range of 10-20mg
Intervention Type
Drug
Intervention Name(s)
Risperidone
Intervention Description
Risperidone 1-6mg
Intervention Type
Drug
Intervention Name(s)
Haloperidol
Intervention Description
Haloperidol 10-20mg
Primary Outcome Measure Information:
Title
Study of metabolic profile
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Study of obesity and diabetes
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 18-40 years Diagnosis of schizophrenia Drug naive on admission Exclusion Criteria: Other psychiatric co-morbidity History of severe physical illness Alcohol and substance abuse or dependence History of pre-existing diabetes or hypertension Family history of hypertension or diabetes
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sahoo Saddichha, DPM
Organizational Affiliation
Central Institute of Psychiatry
Official's Role
Principal Investigator
Facility Information:
Facility Name
Central Institute of Psychiatry
City
Ranchi
ZIP/Postal Code
834009
Country
India

12. IPD Sharing Statement

Citations:
PubMed Identifier
18052574
Citation
Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry. 2007 Nov;68(11):1793-8. doi: 10.4088/jcp.v68n1120.
Results Reference
derived

Learn more about this trial

Metabolic Profile and Anthropometric Changes in Schizophrenia

We'll reach out to this number within 24 hrs